Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.

Mattern MR, Wu J, Nicholson B.

Biochim Biophys Acta. 2012 Nov;1823(11):2014-21. doi: 10.1016/j.bbamcr.2012.05.005. Epub 2012 May 17.

2.

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP.

Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. Review.

3.

Deubiquitinating enzymes as therapeutic targets in cancer.

Lim KH, Baek KH.

Curr Pharm Des. 2013;19(22):4039-52. Review.

PMID:
23181570
4.

The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.

Burger AM, Seth AK.

Eur J Cancer. 2004 Oct;40(15):2217-29. Review.

PMID:
15454246
5.

The therapeutic potential of deubiquitinating enzyme inhibitors.

Colland F.

Biochem Soc Trans. 2010 Feb;38(Pt 1):137-43. doi: 10.1042/BST0380137. Review.

PMID:
20074048
6.

Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.

Dalla Via L, Nardon C, Fregona D.

Future Med Chem. 2012 Mar;4(4):525-43. doi: 10.4155/fmc.11.187. Review.

PMID:
22416778
7.

The proteasome: a novel target for anticancer therapy.

Montagut C, Rovira A, Albanell J.

Clin Transl Oncol. 2006 May;8(5):313-7. Review.

PMID:
16760005
8.

Molecular pathways: targeting proteasomal protein degradation in cancer.

Molineaux SM.

Clin Cancer Res. 2012 Jan 1;18(1):15-20. doi: 10.1158/1078-0432.CCR-11-0853. Epub 2011 Oct 21.

9.

Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development.

Tsukamoto S, Yokosawa H.

Curr Med Chem. 2006;13(7):745-54. Review.

PMID:
16611064
10.

Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.

Driscoll JJ, Dechowdhury R.

Target Oncol. 2010 Dec;5(4):281-9. doi: 10.1007/s11523-010-0165-2. Epub 2010 Nov 27. Review.

PMID:
21125340
11.

The potential of proteasome inhibitors in cancer therapy.

Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O.

Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879 . Review.

PMID:
18491989
12.

Targeting the proteasome pathway.

Tsukamoto S, Yokosawa H.

Expert Opin Ther Targets. 2009 May;13(5):605-21. doi: 10.1517/14728220902866851 . Review.

PMID:
19397479
13.

Targeting E3 ubiquitin ligases for cancer therapy.

Sun Y.

Cancer Biol Ther. 2003 Nov-Dec;2(6):623-9. Review.

PMID:
14688465
14.
15.

Proteasome: an emerging target for cancer therapy.

Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K, Sezer O.

Anticancer Drugs. 2005 Jun;16(5):475-81. Review.

PMID:
15846112
16.

The role of proteasome in malignant diseases.

Moran E, Nencioni A.

J BUON. 2007 Sep;12 Suppl 1:S95-9. Review.

PMID:
17935285
17.

Proteasome inhibitors in cancer therapy: lessons from the first decade.

Orlowski RZ, Kuhn DJ.

Clin Cancer Res. 2008 Mar 15;14(6):1649-57. doi: 10.1158/1078-0432.CCR-07-2218. Review.

18.

Drug discovery and assay development in the ubiquitin-proteasome system.

Berkers CR, Ovaa H.

Biochem Soc Trans. 2010 Feb;38(Pt 1):14-20. doi: 10.1042/BST0380014.

PMID:
20074028
19.

Development of the proteasome inhibitor Velcade (Bortezomib).

Adams J, Kauffman M.

Cancer Invest. 2004;22(2):304-11. Review.

PMID:
15199612
20.

Proteasome inhibitors: a therapeutic strategy for haematological malignancy.

Crawford LJ, Walker B, Irvine AE.

Front Biosci. 2008 May 1;13:4285-96. Review.

PMID:
18508511
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk